

Select Merck-related abstracts accepted for the ASCO 2025 Annual Meeting include (all times in CDT):

Title	Lead Author	Abstract	Session Information
Pimicotinib			
Pimicotinib in tenosynovial giant cell tumor (TGCT): Efficacy, safety and patient-reported outcomes of Phase 3 MANEUVER study	Niu X	11500	Session Title: Sarcoma Date: Sunday, June 1, 2025 Session Time: 9:45 AM – 12:45 PM Presentation Time: 9:45 AM – 9:57 AM Location: S100a
Precemtabart tocentecan (M9140)			
Precemtabart tocentecan (M9140), an anti-CEACAM5 ADC with exatecan payload, in patients with metastatic colorectal cancer (mCRC): Results from the dose optimization of the phase 1 PROCEADE CRC-01 study	Kopetz S	3038	Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Date: Monday, June 2, 2025 Session Time: 1:30 PM – 4:30 PM Location: Hall A
BAVENCIO® (avelumab)			
Avelumab + sacituzumab govitecan (SG) vs avelumab monotherapy as first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC): Interim analysis from the JAVELIN Bladder Medley phase 2 trial	Hoffman-Censit J	4501	Session Title: Genitourinary Cancer—Kidney and Bladder Date: Sunday, June 1, 2025 Session Time: 9:45 AM – 12:45 PM Presentation Time: 9:57 AM – 10:09 AM Location: Hall D2
Differences in patient (pt) characteristics and therapy choice across treatment (tx) groups in locally advanced or metastatic urothelial cancer (la/mUC) in the US: A survey on unmet patient needs	Milloy N	e16561	Session Title: Publication Only: Genitourinary Cancer—Kidney and Bladder
Management and outcomes of rash, peripheral neuropathy (PN), and hyperglycemia (HG) during first-line (1L) treatment (tx) of locally advanced/metastatic urothelial cancer (la/mUC) in a real-world setting	Nizam A	e23275	Session Title: Publication Only: Quality Care/Health Services Research
Real-world safety and effectiveness of avelumab in immune-compromised (IC) and non-IC patients with Merkel cell carcinoma (MCC): Results from a prospective German registry (MCC-TRIM)	Becker J	9543	Session Title: Publication Only: Genitourinary Cancer—Kidney and Bladder
ERBITUX® (cetuximab)			
FIRE-4 (AIO KRK-0114): Randomized study evaluating the efficacy of cetuximab re-challenge in patients with metastatic RAS wild-type colorectal cancer responding to first-line treatment with FOLFIRI plus cetuximab	Weiss L	3513	Session Title: Gastrointestinal Cancer—Colorectal and Anal Date: Sunday, June 1, 2025 Session Time: 11:30 AM – 1:00 PM Presentation Time: 11:36 AM – 11:42 AM Location: Hall D1
First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): Progression-free survival and updated overall survival analyses	Elez E	LBA3500	Session Title: Oral Abstract Session C: Cancers of the Colon, Rectum, and Anus Date: Friday, May 30, 2025 Session Time: 2:45 PM-5:45 PM Presentation Time: 2:45 PM – 2:57 PM Location: Arie Crown Theater